|
|
|
CHILDHOOD STOMACH FLU MAY STOP ASTHMA
Professor Paolo Matricardi of Rome stated in The British Medical Journal that stomach infections early in childhood may help people avoid respiratory allergies and asthma later on. Researchers believe that food-borne bacterial infections in childhood may help the immune system build up a resistance to allergies.
Asthma cases are increasing by up to 50 percent every 10 years. Many scientists think that environmental poisons and pollution are only partly responsible. Matricardi and his research team showed that 1,659 Air Force cadets who had stomach flus early in life and were exposed to food-borne bacteria and the common stomach bacteria, Helicobacter pylori, were less likely to suffer asthma and upper respiratory infections.
Our fear of bacteria and obsession with cleanliness has gone overboard. Matricardi states that “We must improve hygiene to reduce the impact of infectious diseases but at the same time, we must learn how to safely train our immune system, especially during infancy, in order to prevent allergy.” We must realize that childhood illnesses are the training ground for our immune systems. In order for the immune system to develop properly, a few illnesses in early childhood are a good thing.
Source:British Medical Journal
FDA APPROVES ORPHAN DRUG STATUS OF SYSTEMIC
ENZYMES TO TREAT RARE FORM OF CANCER
The FDA has approved the orphan drug application of Wobe-Mugos as an adjunct therapy for multiple myeloma. Wobe-Mugos is a combination of systemic enzymes used successfully in Europe in conjunction with chemotherapy since 1977. Numerous clinical trials have proven its efficacy in reducing the severity of symptoms, extending life span and improving the quality of life of multiple myeloma patients.
The orphan drug application was filed by Marlyn Nutraceuticals of Scottsdale, Arizona. The company conducts extensive in-house research and also collaborates with numerous leading research institutions around the world to develop safe, effective and wholesome solutions to healthcare problems.
Wobe-Mugos is manufactured by Marlyn’s strategic corporate partner, MUCOS Pharma of Germany. For the past 40 years MUCOS has pioneered the research on systemic enzymes and their delivery. MUCOS and Marlyn will now sponsor an extensive double-blind, placebo-controlled trial of Wobe-Mugos at multiple centers in the United States beginning January 2001.
Each year roughly 13,000 Americans develop multiple myeloma, an incurable form of cancer. The disease is characterized by the spread of cancerous B-lymphocytes, the antibody-producing cells of the body. There is no cure. Currently the only treatment is chemotherapy and in some cases, bone marrow transplant.
Orphan drug status makes it possible for companies to develop healthcare solutions for rare diseases such as multiple myeloma. The Orphan Drug Act of 1983 defines an orphan disease as a condition that affects fewer than 200,000 persons in the United States. There are over 5,000 such conditions and they afflict more than 20 million Americans, according to the National Organization for Rare Disorders (NORD).
Marlyn currently distributes Wobenzym, the flagship systemic enzyme formula of MUCOS, which is available as a nutritional supplement in the United States.
For more information about the clinical trials conducted on systemic enzymes or the orphan drug status of Wobe-Mugos, contact Aftab Ahmed, Ph.D., Marlyn’s Director of R&D and Business Development at:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
.
Source: Marylin Nutraceuticals
|
|
